HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Sequential dosing of convalescent COVID-19 plasma with significant temporal clinical improvements in a persistently SARS-COV-2 positive patient.

Abstract
The current global pandemic, SARS-CoV-2 infection, is still extending across the world affecting millions of lives to the date. While new successful vaccines are available with promising outcomes to minimize the spread and to reduce the severity of the disease, optimal therapeutic options still remain elusive. COVID-19 convalescent plasma (CCP) is an investigational treatment option which studies suggesting signals of efficacy and favorable outcomes only for patients treated very early in course of the disease. Benefits of the use of CCP later in the disease remain highly debated and therefore are not common practice. We hereby report a case of severe SARS-CoV-2 infection in a young male patient with prolonged COVID-19 positivity who received repeat doses of CCP treatments later in the disease with temporal clinical improvement. This patient's case highlights the need of further studies evaluating efficacy of repeated dosing of CCP. This also suggests a potential of successful use of CCP later in the disease in selected COVID-19 patients.
AuthorsNoupama Mirihagalle, Priyanka Parajuli, Vidya Sundareshan, Debadoot Saha, Arpan Shah, Francine Chua, Sana Waqar, Vidhya Prakash, Aaron A R Tobian, Evan M Bloch, Louis M Katz, Ruchika Goel
JournalTransfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis (Transfus Apher Sci) Vol. 60 Issue 5 Pg. 103180 (Oct 2021) ISSN: 1473-0502 [Print] England
PMID34247970 (Publication Type: Case Reports, Journal Article)
CopyrightCopyright © 2021 Elsevier Ltd. All rights reserved.
Chemical References
  • Anti-Bacterial Agents
  • Furosemide
Topics
  • Anti-Bacterial Agents (therapeutic use)
  • COVID-19 (complications, diagnostic imaging, therapy)
  • Combined Modality Therapy
  • Diabetes Mellitus, Type 2 (complications)
  • Furosemide (therapeutic use)
  • Humans
  • Hypertension (complications)
  • Immunization, Passive (methods)
  • Male
  • Middle Aged
  • Overweight (complications)
  • Pulmonary Disease, Chronic Obstructive (complications)
  • Recurrence
  • Remission Induction
  • Respiration, Artificial
  • Respiratory Distress Syndrome (diagnostic imaging, etiology, therapy)
  • SARS-CoV-2
  • COVID-19 Serotherapy

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: